Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 61.75% is 454% above its 5-year average of -17.45%, near the high end of its 5-year range (-36.17%–61.75%).
467.01% above its 12-month average of -16.82%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 58.01%.
RETURN ON ASSETS (ROA)
61.75%
RETURN ON ASSETS (ROA) AVG TTM
-16.82%
RETURN ON ASSETS (ROA) AVG 3Y
-22.73%
RETURN ON ASSETS (ROA) AVG 5Y
-17.45%
RETURN ON ASSETS (ROA) AVG 10Y
-14.98%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+467.01%
CURRENT VS 3Y AVG
+371.70%
CURRENT VS 5Y AVG
+453.94%
CURRENT VS 10Y AVG
+512.32%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.55%
median of 582 covered companies
CURRENT VS SECTOR MEDIAN
+316.29%
vs the sector median at left
AnaptysBio, Inc.
Market Cap
$1.41B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
Market Cap
$1.39B
Return on Assets (ROA)
-89.60%
TTM Avg
418.97%
3Y Avg
177.41%
5Y Avg
100.38%
Market Cap
$1.45B
Return on Assets (ROA)
-25.13%
TTM Avg
-5.66%
3Y Avg
-57.10%
5Y Avg
-57.10%
Market Cap
$1.43B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Return on Assets (ROA)
14.98%
TTM Avg
6.07%
3Y Avg
5.42%
5Y Avg
6.72%
Market Cap
$1.36B
Return on Assets (ROA)
-21.52%
TTM Avg
-21.52%
3Y Avg
-21.52%
5Y Avg
-21.52%
Market Cap
$1.48B
Return on Assets (ROA)
-16.72%
TTM Avg
-18.71%
3Y Avg
-15.50%
5Y Avg
-12.14%
Market Cap
$557.04M
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
-52.36%
Market Cap
$1.49B
Return on Assets (ROA)
10.96%
TTM Avg
-5.00%
3Y Avg
-12.25%
5Y Avg
-27.07%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.41B | 61.75% | -16.82% | -22.73% | -17.45% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -89.60% | 418.97% | 177.41% | 100.38% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | -25.13% | -5.66% | -57.10% | -57.10% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 14.98% | 6.07% | 5.42% | 6.72% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.36B | -21.52% | -21.52% | -21.52% | -21.52% |
| GH Research PLC (GHRS)vs › | $1.48B | -16.72% | -18.71% | -15.50% | -12.14% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $557.04M | -41.48% | -39.59% | -35.47% | -52.36% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 10.96% | -5.00% | -12.25% | -27.07% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.32B | -32.81% | -32.81% | -32.81% | -32.81% |
ROA
61.8%
ROE
1849.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -3.63% |
| 2024-12-31 | -30.02% |
| 2023-12-31 | -36.17% |
| 2022-12-31 | -21.09% |
| 2021-12-31 | -8.99% |
| 2020-12-31 | -4.78% |
| 2019-12-31 | -22.37% |
| 2018-12-31 | -12.11% |
| 2017-12-31 | -9.13% |
| 2016-12-31 | -6.85% |
| 2015-12-31 | -9.60% |
| 2014-12-31 | 0.93% |
| 2013-12-31 | -141.67% |
